Jupiter Topco LLC Makes New $27.58 Million Investment in CAMP4 Therapeutics Corporation $CAMP

Jupiter Topco LLC purchased a new stake in CAMP4 Therapeutics Corporation (NASDAQ:CAMP) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 6,307,636 shares of the Wireless communications provider’s stock, valued at approximately $27,581,000. Jupiter Topco LLC owned 0.10% of CAMP4 Therapeutics as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Bridgeway Capital Management LLC acquired a new stake in shares of CAMP4 Therapeutics in the second quarter valued at $36,000. Jefferies Financial Group Inc. purchased a new position in CAMP4 Therapeutics in the fourth quarter valued at $70,000. Bank of America Corp DE acquired a new position in CAMP4 Therapeutics during the 4th quarter worth $86,000. Goldman Sachs Group Inc. acquired a new position in CAMP4 Therapeutics during the 4th quarter worth $115,000. Finally, OMERS ADMINISTRATION Corp purchased a new stake in CAMP4 Therapeutics during the 4th quarter worth about $115,000.

CAMP4 Therapeutics Trading Up 0.2%

Shares of CAMP4 Therapeutics stock opened at $4.15 on Friday. The company has a fifty day simple moving average of $4.13 and a 200-day simple moving average of $4.36. CAMP4 Therapeutics Corporation has a 12-month low of $1.41 and a 12-month high of $7.75. The stock has a market cap of $260.41 million, a price-to-earnings ratio of -1.79 and a beta of 0.22.

CAMP4 Therapeutics (NASDAQ:CAMP) last announced its quarterly earnings results on Thursday, August 13th. The Wireless communications provider reported ($0.58) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.34). CAMP4 Therapeutics had a negative return on equity of 252.79% and a negative net margin of 2,543.74%.The company had revenue of $1.78 million for the quarter. On average, analysts forecast that CAMP4 Therapeutics Corporation will post -0.57 earnings per share for the current fiscal year.

Insider Buying and Selling at CAMP4 Therapeutics

In other news, Director Andrew J. Schwab sold 114,700 shares of the business’s stock in a transaction dated Thursday, August 20th. The stock was sold at an average price of $4.54, for a total value of $520,738.00. Following the completion of the sale, the director directly owned 2,465,298 shares of the company’s stock, valued at approximately $11,192,452.92. The trade was a 4.45% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Richard A. Young bought 16,378 shares of the firm’s stock in a transaction that occurred on Monday, August 3rd. The stock was purchased at an average cost of $1.65 per share, with a total value of $27,023.70. Following the completion of the transaction, the director owned 186,388 shares in the company, valued at approximately $307,540.20. This trade represents a 9.63% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders acquired 36,031 shares of company stock valued at $59,451 and sold 193,613 shares valued at $888,037. Corporate insiders own 21.69% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on CAMP shares. Zacks Research raised CAMP4 Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, August 17th. Weiss Ratings upgraded shares of CAMP4 Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, August 14th. UBS Group set a $15.00 target price on shares of CAMP4 Therapeutics in a report on Friday, August 14th. Piper Sandler reiterated an “overweight” rating and issued a $15.00 price target (up from $12.00) on shares of CAMP4 Therapeutics in a research note on Friday, August 14th. Finally, JPMorgan Chase & Co. upgraded shares of CAMP4 Therapeutics from a “neutral” rating to an “overweight” rating and boosted their price target for the stock from $5.00 to $9.00 in a report on Tuesday, June 16th. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $9.56.

About CAMP4 Therapeutics

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.